By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion ...

Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal ...

Explore the U.S. patents Merck deploys to stymie competition and keep revenues for its blockbuster cancer drug flowing as ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

A game changer in cancer treatment, Keytruda, works by harnessing the body’s immune system to attack cancer cells. While its ...

In a yearlong investigation led by the International Consortium of Investigative Journalists, reporters from more than 37 ...

Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...